Hualing Pharmaceutical (02552) rose more than 10%, up 10.11% at press time to HK$2.07, with a turnover of HK$5.38 million.
The Zhitong Finance app learned that Hualing Pharmaceutical (02552) had risen more than 9%, and at press time, it had risen 10.11% to HK$2.07, with a turnover of HK$5.38 million.
According to the news, it was noticed on the 18th at the site of the 2023 national health insurance negotiations that Hualing Pharmaceutical representatives were “named” by the staff at the national talks site at 14:14 and entered the negotiation room on the second floor to conduct national talks. However, for an hour now, the reporter has not seen Hualing's business representatives come down the main stairs, or this means that the negotiations have not yet been completed.
According to information, Hualing Pharmaceutical, as a biotech company that has just commercialized its first product, only covered one variety in national negotiations this year, namely dogliadine. This variety is a glucokinase activator developed by Hualing Pharmaceutical after its introduction. It is also the first GKA drug approved in the world. Hualing Pharmaceutical has high hopes that this new drug for diabetes will be rapidly released after entering medical insurance.